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Summary.-The effect oflymphocytes from normal mice on the growth of asyngeneic,
radiation-induced, T-cell-derived lymphoma was investigated. Thymus and spleen
cells enhanced the growth of admixed lymphoma cells in a reproducible manner.
Growth enhancement was manifested by the earlier appearance and higher final
incidence of tumours. Lymphocytes also enhanced the growth of radiation-damaged
lymphoma cells. The enhancing activity of spleen cells was predominantly a property
of T cells, since it was abolished by treatment with anti-0 serum plus complement
and significantly less in spleen cells of nude mice. Tumour-enhancing thymocytes
seem to belong to the immature thymic subpopulation, as indicated by their binding
to peanut agglutinin.
ENHANCEMENT OF TUMOUR GROWTH as a
result of the interaction between tumour
and lymphoid cells has been reported in a
variety of experimental systems (Fidler,
1973, 1974; Ilfeld et al., 1973; Prehn,
1972). The growth of the 3LL tumour of
spontaneous origin and ofsome chemically
induced fibrosarcomas was enhanced by
lymphocytes of tumour-bearing mice
(Umiel & Trainin, 1974; Gabizon et al.,
1976; Manor et al., 1976). In addition,
tumour-enhancing lymphocytes from mice
bearing a chemically induced fibrosarcoma
were found to abolish the activity of
tumour-inhibiting lymphocytes when
mixed together (Small & Trainin, 1976).
The tumour-enhancing effect can also be
mediated by lymphoid cells of normal
mice, as shown in several instances.
Deckers et al. (1971) reported facilitation
of tumour growth by normal spleen cells.
The development of lung metastases was
stimulated when lymphoid cells from
normal and tumour-bearing mice were
mixed with B-16 tumour cells before
injection (Fidler, 1974). Enhanced growth
of the 3LL carcinoma was induced with
spleen T cells (Umiel & Trainin, 1974) and
thymus cells (Umiel et al., 1978) of normal
mice. Recently enhancement of YAC
lymphoma cells by normal spleen cells in
the Winn assay has been reported by
Gillette et al. (1978).
The significance of these data for the
role of lymphocytes, and more specifically
of T cells, in the growth of primary
tumours remains uncertain. The reduced
growth of some primary tumours in T-
cell-depleted hosts (Gillette & Fox, 1975)
may be related to the lack of tumour-
enhancing T-cell activity. Data on the
development of spontaneous tumours in
nude mice (Rygaard & Povlsen, 1976)
seem to be compatible with a tumour-
enhancing activity of T cells. The im-
munostimulatory effects on tumour
growth have been extensively studied by
Prehn (1976), who has postulated that the
development of incipient tumours is
actually stimulated by the immune re-
sponse. Understanding of the mechanisms
by which lymphocytes enhance tumour
growth will probably help to evaluate the
role of this phenomenon in the host-
tumour relationship. In the present study,
we have investigated some aspects of the
enhancement of tumour growth by lym-
phocytes from normal mice, including theA. GABIZON AND N. TRAININ
type of lymphocyte involved. We have
examined here the phenomenon of en-
hancement with the early transplantation
generations of a syngeneic, T-cell-derived,
radiation-induced lymphoma.
MATERIALS AND METHODS
Animals-Two- to 4-month-old inbred
mice from the Animal Breeding Centre at the
Weizmann Institute of Science were used
throughout these experiments. The strains
used were BALB/c (H-2d), C57BL/6 (H-2b),
BALB.B (H-2b) and (BALB/c x C57BL/6)Fi,
as well as homozygous (nu/nu) and hetero-
zygous (nu/+) nude athymic mice with the
BALB/c genotype.
Tumour.-The tumour used inthese experi-
mentswasalymphomainducedbyweeklyfrac-
tionated irradiation (1.7 Gy x 4) in BALB/c
mice, kindly provided by Professor N.
Haran-Ghera (Weizmann Institute, Rehovot).
This lymphoma was kept frozen after induc-
tion and then thawed, and used for this study
during the first 15 serial transplantations in
syngeneic mice. After s.c. injection, it grows
locally as a solid nodule with a volume-
doubling time of2 days up to a size of 12 mm.
The TD50 in syngeneic BALB/c mice is
between 103 and 5 x 103 lymphoma cells
(Figure). Metastases mainly develop in the
spleen, wherethey can bedemonstrated about
1 week after the local tumour becomes palp-
able, by the growth of tumours from trans-
plants ofspleen cells into syngeneic recipients.
Liver and lymph nodes are infiltrated later
during the course of tumour growth. All the
lymphoma cells are sensitivetotreatmentwith
anti-0 serum plus complement, indicating
that it is a T-cell-derived lymphoma. As
shown in Table I, a cell-free extract of this
lymphoma prepared as described by Haran-
Ghera et al. (1977) was found to be leukaemo-
genic after intrathymic injection in irradiated
recipients, indicating the presence of an
oncogenic virus in the lymphoma cells.
Preparation of cell suspensions.-Spleens,
thymuses or lymph nodes were aseptically
removed, and cell suspensions prepared by
pressing the organ through a fine stainless-
steel mesh into cold Dulbecco's modified
Eagle's medium (MEM).
Lymphoma cell suspensions were prepared
as follows: the local tumour was aseptically
removed from donor animals and the necrotic
TABLE I.-Leukaemogenic activity of the,
cell-free extract of a radiation-induced
lymphoma
Treatment of mice*
Cell-free
extractt Irradiationt
+ +
+
No of
leukaemic
mice/total
8/10
1/12
0/10
Mean
survival
time + s.e.
118+13
129
* 5-week-old BALB/c mice observed for 6 montlhs.
t Injected intrathymically.
$ 4 Gy whole-body.
tissue discarded. The tumour was minced
with scissors into small fragments, which
were washed several times in MEM and
trypsinized for 15 min in a 0 25% solution
of trypsin. The suspension was then filtered
through a metal sieve, centrifuged twice to
remove the trypsin, and finally resuspended
in fresh MEM. Only tumour cells excluding
trypan blue, generally >90% of the total,
were counted.
Anti-0 serum.-The serum was produced
following Reif and Allen's procedure (1966)
of repeated injections of C3H/eB thymocytes
into AKR/J mice. Before use, it was absorbed
in a liver powder prepared from C3H/eB mice.
The resulting antiserum killed all the thymo-
cytes at a 1: 64 dilution. For the anti-0
treatment, cells were incubated in an ice bath
for 1 h with the antiserum, then washed and
reincubated with guinea-pig complement
(lyophilized complement, GIBCO) for 30
min at 37TC. Control cells were incubated with
normal AKR/J serum and complement.
Peanut agglutinin cell fractionation.
Separation of thymus cells with peanut
agglutinin (PNA) was performed according
to the method ofReisner et al. (1976). Briefly,
108 cells in 0-25 ml of PBS were mixed with
1 mg of PNA in 0-25 ml in a small Falcon
plastic tube and left at room temperature for
10 min. The mixture was then gently layered
with a Pasteur pipette on the top of a 50%
FCS solution in PBS. When the agglutinated
fraction settled on the bottom of the tube, it
was carefully aspirated with a Pasteur
pipette. The upper layer of non-agglutinated
thymocytes was removed with a Pasteur
pipette into another tube. The lectin was
removed from both fractions by a 10min
incubation in 2 ml of 0-3M D-galactose. The
separated cells were washed twice in PBS,
resuspended in MEM and brought to the
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required cell concentration. The viability of
cells was checked by trypan-blue exclusion.
Winn test.-The action of lymphoid cells
on tumour growth was tested by the Winn
assav (Winn, 1961). Lymphoid cells and
tumour cells were prepared at the desired
concentrations and mixed immediately before
injection. The cells were inoculated s.c. into
the interscapular space of normal, syngeneic
mice. A control group ofmice received tumour
cells alone. The animals were regularly
palpated and the appearance of tumours
recorded. Tumours could be detected by
palpation when their size was 2-3 mm in
diameter.
Irradiation.-Irradiation was provided by
a Cobalt 60y source (Atomic Energy Ltd,
Canada; y beam 15nm, dose rate lOGy/min).
Cells were irradiated in MEM suspension
immediately before their use in the Winn test.
Statistical analysis.-The statistical sig-
nificance of the results was analysed by the
non-parametric, ranking test of Wilcoxon.
Values of P <005 were considered sig-
nificant.
RESULTS
Effect of normal lymphoid cells on the in
vivo growth ofsyngeneic lymphoma cells
The administration of lymphoma cells
mixed with cells obtained either from
spleen or from thymus of normal mice
consistently caused tumour enhancement.
As shown in Table II, the latency period
of tumour growth was significantly
shortened by the addition of lymphoid
cells. Tumour enhancement was greater
if the lymphocyte:tumour cell ratio was
increased (Table II, Exp. 3). If the num-
ber oflymphoma cells was reduced to sub-
optimal doses, the enhancement was
manifested by an increase of the final
tumour incidence (Table II, Exp. 4, 5
and 8). Tumours were seen in mice in-
jected with as few as 102 lymphoma cells
mixed with spleen cells (Table II, Exp. 5).
Since_ 104 lymphoma cells are required
to cause a 100% tumour incidence when
TABLE II.-Enhancement of lymphoma growth by lymphoid cells of normal mice
Cells injectedt
No. of No. of
tumour lymphoid
Exp. cells cells
1
2
3
4
5
6
7
8
105
105
105
105
105
105
105
103
103
102
102
105
105
104
104
103
103
5x 106
5 x 106
106
107
5x 106
5 x 106
5x 106
5x 106
Sx 106
Tumour:
lymphoid
cell
ratio
Spleen
1:50
1:50
1:10
1:100
1:5000
1:50,000
Thymus
1:50
1:500
1:5000
Lymphnode
9 5x 104
5x 104 2 5x 106 1:50
Mean day of
tumour
appearance
+s.e.
(tumour take)
21+1 (9/9)
16 + 0 (9/9)***T
22+2 (9/9)
16+ 1 (9/9)*
21 + 1 (10/10)
17+1 (9/9)*
15+1 (10/10)***
21 (1/5)
16 + 0 (5/5)***
31 (1/10)
24+2 (8/8)***
24 + 0 (9/9)
19+0 (9/9)**
25 + 3 (5/5)
16+0 (8/8)**
(0/5)
24+2 (5/5)***
24 + 1 (8/9)
23+1 (8/9) n.s.
t Cells were injected s.c. into syngeneic normal BALB/c mice. The tumour was a radiation-induced lym- phoma of BALB/c mice. Donors of lymphoid cells were normal BALB/c mice.
t Wilcoxon test P values calculated vs the control group of each experiment (injected with tumour cells alone).
***, P < 0-01; **, P < 0-02; *, P < 0-05; n.s. =not significant.
Mean
survival
time after
tumour
appearance
(days)
24-6
24-2
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FIGUTRE-Transplantability of graded (loses of
lymphoma cells (s.c. injection into normal
syngeneic BALB/c mice).
injected alone (Figure), the addition of
5 x 106 lymphoid cells increases 100-fold
the tumorigenic capacity of lymphoma
cells.
Once the tumours were palpable, we
could not detect any difference in volume-
doubling time between mice injected with
tumour cells alone and those injected
with tumour cells plus lymphoid cells
(data not shown). This is in agreement
with the observation that the interval
between tumour appearance and death
was not modified by the presence of
lymphocytes in the inoculum (Table II,
Exp. 2) suggesting that the tumour-
enhancing effect is restricted to the latent
period. In a single experiment (Table II,
Exp. 9) peripheral lymphnode cells, in
contrast to spleen and thymus cells,
caused no significant enhancement of
lvmphoma growth.
The ability of lymphoid cells to increase
the tumorigenic capacity of in vitro
irradiated lymphoma cells was then ex-
amined. As seen in Table III, spleen cells
of normal donors accelerated tumour
appearance from tumour cells irradiated
with a dose of 10 Gy. Moreover, these
lymphoid cells allowed the growth of
tumour inocula made non-tumorigenic by
doses of 40 and 100 Gy. The transfer of an
TABLE III. Effect of spleen cells from
normal mice on growth of irradiated
lymphoma cells*
Radiation
dose to
lymphoma
cells (Gy)
10
40
100
Final t,umour incidtence (AMean
day of tumouri app. ± s.e.)
--A
Lymphoma Lymphoma cells
cells only + spleen cells
5/5(19+1) 5/5(14+1)
5/5(32+3) 5/5(18+1)
0/5 5/5 (21 + 1)
0/5 5/5 (24 + 1)
* 2 X 105 lymplioma cells injectect s.c. either alone
or with spleen cells into syngeneic BALB/c mice.
Tumouir: spleen cell ratio 1: 50.
oncogenic virus from the irradiated lymph-
oma cells to the lymphocytes is certainly
not relevant to these results, because of
the long latent period of RadLV-induced
lymphomas (Haran-Ghera et al., 1977; and
see Table I) and because tumour cells
derived from a mixture of irradiated
lymphoma cells and (BALB/cx C57BL/
6)F1 lymphocytes grew in BALB/c hosts
and were negative for the H-2b marker as
tested by anti-H-2b and complement
cytotoxicity (data not shown).
In additional experiments, we investi-
gated whether tumour enhancement was
detectable in immunosuppressed hosts.
For this purpose, mice received whole-
body irradiation (6 Gy) and were subse-
quently challenged with lymphoma cells
with or without thymus cells. As seen in
Table IV, irradiation produced no signifi-
cant change in the number of tumour
takes and time to tumour appearance in
mice injected with tumour alone. More-
TABLE IV.-Effect ofwhole-body irradiation
on the growth of lymphoma cells
Mlean day of tumour
appearance + s.e.
Lymphoma T}ymus Irra- (final tumour
d.ells* (cellst dliationt incidence)
5x 1(4 _ 18+0(5/5)
5X104 + 17+0(5/5)
104 - 24+2(5/5)1p<00
104 5 x 106 - 18+ 1 (8/8)
104 + 25+2(5/5) P<002
104 5X106 + 16±0(8/8)f
* Injected s.c. into syngeneic BALB/c mice.
t From normal BALB/c mice.
t 6Gy wlhole-bodv 24 h before tumouir challenge.
I
rAs
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over, when lymphoma and thymus cells
were injected together, enhancement was
equal in normal and irradiated mice.
These results suggest that, under these
experimental conditions, the growth of
the lymphoma is not affected by immuno-
suppressive procedures such as irradiation.
TABLE V. Enhancement of lymphomna
growth by thymus cells of different genetic
origin
Cells injected*
Thymus
cells
(5 x 106) OrIigill
+ BALB/C
BALB.B
C57BL/6
Alean (lay
Final of tumour
tumour appearance
incidlence + s.e.
0/10
6/10
4/10
6/10
(20+ 3)
(19± 2)
(19 + 2)
TABLE VI. Involvement of spleen T cells
in enhancement of lymphoma growth*
Cells injected
Tumour only
Tumour + normal serum and
C'-treated spleent
Tumour +anti- 0 and
C'-treated spleent
Tumour only
Tumour +nu/ + spleen+
Tumour + nu/nu spleen$
Mean
day of
tumour
appearance
+s.e.§ P
24+1
0-02
18+0
0-02
24+1 -
29 +1 10-01
21 + 1
26 + 2 }0 05
* 105 lymphoma cells, eithler with or without
spleen cells were iijected s.c. into syngeneic BALB/c
mice.
t Tumour: spleen cell 1 :25.
+ Tumour: spleen cell 1:100.
§ In every experiment the final tumour incidence
was 9/9.
* 104 tumour cells (lerive(d from a radiation-
iniduced lymphoma of BALB/c mice were injected
either alone or together witlh tlhymtus cells into semi-
allogeneic (BALB/c xC57BL/6)-F1 hosts. In tlhese
mice, the lymplhoma TD50 is higher than in BALB/c
mice. This explains why no tumouir takes were
obtained with 104 lymphoma cells alone in this
experiment.
As seen in Table V, enhancement was
equally evident with syngeneic and allo-
geneic (H-2b) thymus cells on BALB/c
(BALB.B) or C57BL/6 backgrounds, in-
dicating that the genetic origin of thymus
cells is not relevant to enhancement.
(BALB/c x C57BL/6)F1 mice were used as
recipients in this experiment in order to
avoid the possibility of host-vs-graft
reaction against H-2b-bearing lympho-
cytes.
Whether or not the injection ofparental
thymus cells causes a GvH reaction, hence
host immunosuppression, is unlikely to
affect lymphoma growth, given the results
previously shown with radiation-immuno-
suppressed mice.
Role ofT lymphocytes in the enhancement of
lymphoma growth
Previous work on the characterization
of tumour-enhancing lymphocytes has
emphasized the predominant involvement
ofT cells in various tumour models (Umiel
& Trainin, 1974; (Gabizon et al., 1976;
Small, 1977). It was important, therefore,
to check whether spleen T cells are in-
volved in the enhancement of lymphoma
growth in the present experimental model.
The results presented in Table VI indicate
that treatment with anti-6 serum totally
abolished the enhancing effect of spleen
cells from normal mice, and that spleen
cells from athymic (nu/nu) mice were
significantly less effective than spleen cells
from theirheterozygous littermates (nu/ + )
in tumour enhancement. These results,
together with the enhancing activity of
thymus cells (see Table II, Exp. 6-8)
point to a predominant role of thymus-
derived cells in the enhancement of
lymphoma growth.
Maturity and radiation-8en8itivity
tumour-enhancing lymphocytes
of
An attempt was made to characterize
some features of the tumour-enhancing
lymphocytes. Thymus cells can be separ-
ated into 2 subpopulations by peanut
agglutinin (PNA) (Reisner et al., 1976).
The cells which bind to PNA are charac-
teristically immature lymphocytes with a
low immunological capacity, whereas
those which do not bind to PNA are
mature and immunocompetent lympho-
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TABLE VII.-Effect of fractionation with
PNA on tumour enhancement by thymus
cells
Cells injected
Lymphoma* only
Lymphoma+unfractionated
thymus cellst
Lymphoma +PNA+ thymus
cellst
Lymphoma+PNA- thymus
cellst
* 104 lymphoma cells were inject
without thymus cells into syngeneic
t Lymphoma:thymus cell ratio 1:
t Comparison with control (lymph
§ In every experiment the final tu
was 100%.
cytes apparently equivalent
sone-resistant thymic cells (I
1976). In order to test wheth4
enhancement is caused select
of these subpopulations, we
thymus cells with PNA and
in the Winn assay. As seen i
while PNA+ cells were capat
enhancement, no significant
of tumour appearance was
PNA- cells. This suggests
enhancement is characterist
population of immature T ce
Finally, the effect of radi
tumour-enhancing capacity
cells was investigated. As sh4
VIII, the tumour-enhancing
Mean day
oftumour
appearance
+ s.e.§ Pt
25+2
16+0 <0 01
1R 6 1-~ I ^-- 2
spleen cells was suppressed by 8 Gy and
20 Gyirradiation when 105lymphoma cells
were injected. It was also found that the
increased tumour incidence caused by
thymus cells when 103 lymphoma cells
were injected was gradually cancelled by
8 Gy and 20 Gy irradiation ofthymus cells.
DISCUSSION
l -r 1 IC- VIVIL The present investigations indicate that
23+2 n.s. T cells from normal mice enhance the
ted s.c. with or growth of lymphoma cells in in vivo trans-
- BALB/c mice. fertests. This effect was consistently found
500. with spleen and thymus cells and was
ioma only). ..
imour incidence expressed as an earlier uumour appearance,
when a supraoptimal number of lymph-
oma cells was injected, and by a higher
to the corti- tumour incidence, when a suboptimal
1eisner et al., number of lymphoma cells was injected.
er lymphoma Differences of several days in tumour
tivelv by one appearance were reflected by striking
fractionated changes in tumour size, due to the short
tested them volume-doubling time of this tumour
in Table VII, (2 days). This stresses the biological rele-
)le of causing vaiice ofthe data with supraoptimal doses
modification oflvmphoma cells. The enhancing activity
found with of lymphoid cells was also manifested on
that tumour the growth of irradiated lymphoma cells.
ic of a sub- The development of tumours from mix-
lls. tures of irradiated lymphoma cells and
iation on the lymphoid cells might be explained by an
of lymphoid enhancing effect of the latter on a small
own in Table remaining number of viable tumour cells.
X activity of This is supported by the fact that the
TABLE VIII.-Radiosensitivity of the enhancing effect of lymphoid cells on k,smphoma
growth
Radiation Mean
dose to day of
lymphoid tumour Final
Cells injected cells appearance tumour
per mouse* (Gy) + s.e. incidence P
L (105) - 16+0 (7/7) < 01
L (105) +S (5 x 106) 12+0 (7/7) }< 001
L(105)+S(5X106) 8 18+0 (7/7)
L (105) +S (5x 106) 20 17 + 1 (7/7) } n.s.
L(103) - X10)20+0 (1/6) <}-0 L (103) +TT( 0617 - +1 (8/8) < 01
L (103) +T (5 x 106) 8 21+ 2 (4/8) <001
L (103) +T (5 x 106) 20 - (0/6) n.s.
* Lymphoma cells (L) injected s.c. with or without lymphoid cells from spleen (S) or thymus (T) into
syngeneic BALB/c mice.
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injection of as few as 102 lymphoma cells
led to 100% tumour incidence when
lymphoid cells were added in the inoculum
(Table II). The possibility of a helper
effect on the repair capacity of sublethally
damaged tumour cells must also be con-
sidered, especially since cell-to-cell con-
tacts, which are known to influence the
repair process of sublethal injury (Durand
& Sutherland, 1972) may occur between
lymphoma and lymphoid cells.
Our experiments with anti-6 serum, and
with spleen cells from nude mice, indicate
a predominant role of T cells in the en-
hancement of lymphoma growth. The
fractionation of thymocytes with peanut
agglutinin further indicates that a sub-
population of immature T cells, rather
than the whole thymus-cell population,
is responsible for the tumour-enhancement
effect, suggesting that the tumour-en-
hancing properties of T cells are cancelled
out during maturation. These results are
similar to those of Umiel et al. (1978) with
other tumours.
The link between immature T lympho-
cytes and tumour-enhancement is further
supported by the experiments of Small
(1979) in which TdT activity, a marker of
early thymocytes (Barton et al., 1976) was
increased in spleen cells oftumour-bearing
mice with tumour-enhancing activity. The
finding that peripheral lymphnode cells
from normal mice showed no tumour-
enhancing activity is in agreement with
the high level of maturation and immuno-
competence of lymphnode T cells (Trainin
et al., 1979).
We have shown previously that the
enhancing effect of spleen cells from mice
bearing a chemically induced fibrosarcoma
was not tumour specific (Gabizon et al.,
1976). Together with this, the present
observations indicate that a non-sensitized
lymphoid population is capable of tumour
enhancement, suggesting that a process of
specific immunological recognition is not
necessarily involved in tumour enhance-
ment. Yet tumour antigens could interact
wA'ith potentially tumour-enhancing
lymphoid cells in situ after inoculation of
40
the lymphoid-tumour-cell mixture. How-
ever, the lack of difference in the enhanc-
ing effects of lymphoid cells of different
genetic origin (Table V) argues against the
relevance of immunological recognition
phenomena. Tumour enhancement by
allogeneic, as well as syngeneic, lympho-
cytes has been shown in other experi-
mental models, including spleen cells of
tumour-bearing hosts (Manor et al., 1976)
and in vitro tumour-sensitized lympho-
cytes (Small & Trainin, 1975).
The enhancing effect of lymphoid cells
was abrogated by irradiation, indicating
that tumour enhancement is not due to a
simple feeder effect of dead or irradiated
cells similar to the Revesz effect (Revesz,
1958) but to an active process of living
cells. In addition, we have found no
enhancement of lymphoma growth with
supernatants of lymphoid cells (data not
shown). It is not clear whether tumour
enhancement involves suppression of host
resistance, or a direct stimulation of
tumour cells by transferred lymphocytes.
Hellstrom & Hellstrom (1978) have pre-
sented evidence for the existence of a
suppressor, radiosensitive spleen T cell in
normal and tumour-bearing mice, which
enhances tumour growth. However, the
possibility ofan immunostimulatory effect
was not totally discarded (Hellstrom et al.,
1978). As shown in this paper, the fact
that lymphoid cells could still enhance
tumour growth in radiation-immuno-
suppressed animals is against a sup-
pressive mechanism. A similar result was
reported by Carnaud et al. (1974) with
another tumour model, suggesting tumour
stimulation by enhancing lymphoid cells.
The nature of a putative stimulatory in-
teraction between lymphoma and T cells
has not been investigated, but a specific
response of this T-cell-derived tumour to
growth factors of T-cell origin (Morgan et
al., 1976) should be considered.
The phenomenon of tumour enhance-
ment may be especially relevant to
lymphomas rather than other solid, non-
lymphoma tumours. Most mouse lymph-
omas originate and metastasize in the
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vicinity of large concentrations of lymph-
oid cells, including T cells. There is a
possibility that small nests of transformed
cells are stimulated to proliferate and
grow into overt clinical disease in environ-
ments such as the thymus by a similar
interaction to that found in the present
experiments.
We thank Professor N. Haran-Ghera for helpful
discussions during the course of this work.
Nathan Trainin is the Harold L. Korda Professor
of Cancer Research.
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